Biolog-id Partners With AirMed to Help Enhance Visibility, Availability, and Traceability of Life-saving Blood Components
Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today its partnership with AirMed – one of the first air medical transport programs in the US. As part of this partnership, biolog-id’s cutting-edge technology will provide digital visibility to the inventory of red blood cells and liquid plasma across 5 locations in the state of Utah, covering one of the largest geographical areas in the nation, routinely transporting patients not only from Utah, but also from Colorado, Wyoming, Nevada, Montana, and Idaho.
Biolog-id’s blood components management platform will support the inventory replenishment of the different bases, as well as the traceability and documentation of the units selected by the teams at the AirMed bases.
“We are pleased to cooperate with the biolog-id team on the deployment of this technology across our operation,” said Cory Cox, AirMed Outreach Coordinator & Flight Paramedic at AirMed. “We are committed to delivering the highest quality of care to our patients and strive for excellence in every aspect of our profession. The cooperation with biolog-id perfectly aligns with this mission by ensuring the availability of some of the most critical life-saving tools we have at our disposal.”
“Cooperating with an inspiring organization like AirMed is a natural expansion of our current customer base of community donor center and hospital blood banks,” said Troy L. Hilsenroth, CEO biolog-id LLC. “As a former firefighter I am particularly excited about our technology supporting the important mission of the courageous men and women at AirMed.”
The biolog-id technology is compatible across multiple systems, software, and hardware. That flexibility of the biolog-id platform, coupled with a customer-centric innovation focus, facilitates the development of dedicated tools that address the changing conditions in the industry. With an expanding customer base in the US and worldwide, this combination drives the ability to efficiently configure biolog-id’s solution. While addressing the unique needs of both donor centers and hospital blood banks, this further enables our ability to effectively scale.
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About ARUP Laboratories
ARUP Laboratories is a national nonprofit and academic reference laboratory at the forefront of diagnostic medicine. We are a CAP-, ISO 15189-, and CLIA-certified diagnostic lab with more than 35 years of experience supporting clients through unparalleled quality and service. Our forward-thinking community of academic experts and consultants are here to empower our clients with the most current industry knowledge and unparalleled guidance.
Company URL: https://www.aruplab.com/about
About U-Health AirMed:
AirMed was established on June 16, 1978, as the eighth air medical transport program in the nation. We fly trauma, burns, medical, pediatric, neonate, high-risk OB, and cardiac assist device patients 24 hours a day with six helicopters and two airplanes placed throughout northern Utah and Wyoming. We use the most state-of-the-art equipment available, which includes digital capnography, invasive line management, and intra-aortic balloon pumps for transport. We utilize cutting-edge airway technology including video laryngoscopy, advanced portable ventilators, and a variety of adjuncts for securing difficult or complex airways.
Company URL: https://healthcare.utah.edu/airmed/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Appoints Nicolas Mirzayantz President of IFF’s Nourish Division28.7.2021 23:00:00 EEST | Press release
IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, current President, Scent, has been appointed President of IFF’s Nourish division, effective September 1, 2021. Mr. Mirzayantz will succeed Kathy Fortmann, current President, Nourish, who has decided to pursue other opportunities outside of IFF. IFF veteran and current President, Global Consumer Fragrances, Christophe de Villeplee, will assume transition into the role of President, Scent. “We could not be more pleased to have Nicolas lead our Nourish division,” said IFF Chairman and CEO, Andreas Fibig. “Nicolas is joining a Nourish division with a tremendous opportunity to build on significant sales momentum and strong customer interest in IFF’s differentiated portfolio and capabilities. He has been an invaluable member of our leadership team, with an unparalleled ability to create a culture of innovation and deliver creative and winning solutions to our customers while consistently strengthening the business through growth and ma
Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System28.7.2021 19:26:00 EEST | Press release
Stilla Technologies, the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industry’s first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today. This represents a broad portfolio expansion of the Company’s original three-color naica® system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software. The commercial launch of the six-color naica® system is scheduled for Fall 2021. “There is undeniable value in detecting and quantifying multiple mutations, viruses and biomarkers from a single sample. The cost versus depth tradeoffs of NGS make it impractical for the routine testing of many samples per day, while multiplex qPCR lacks the precise quantitation a
Q4 Helps Public Companies and Investment Firms Keep Their Teams Aligned and Informed28.7.2021 16:00:00 EEST | Press release
Q4 Inc. announced today it is applying its unique expertise in delivering mission-critical virtual events to help public companies, buy-side and sell-side firms build transparency, trust and excitement across a widely dispersed workforce. With the seismic shift in working models giving employees increasing flexibility to work both in remote or hybrid setups, maintaining a strong internal communications platform to globally distributed teams is vital for companies across all industries. Simultaneously, the commitment to providing a sustainable work environment and strong corporate culture continues to intensify as companies seek to implement successful ESG policies and programs. Q4’s new Corporate Town Hall subscriptions combine technology and a premium end-to-end service model to help its capital markets clients communicate strategy and best practices, provide quarterly business reviews, host sales kick-offs, and ultimately foster the inclusive culture they have worked so hard to devel
ZS Elects Pratap Khedkar to CEO28.7.2021 16:00:00 EEST | Press release
Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/ Pratap Khedkar, CEO, ZS (Photo: Business Wire) Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about. Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global
Dixa, the Next-Gen CX Platform, Raises $105M Series C to Transform Customer Service Worldwide28.7.2021 15:30:00 EEST | Press release
Founded as a customer service solution that evolved into a customer engagement platform, European company Dixa today announced a Series C funding round totaling $105M. The company is leading the change from customer service to value creation with a multiexperience approach, challenging the status quo and delivering value-driven experiences that generate results for businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005430/en/ Dixa Founding Team (Photo: Business Wire) The Series C round is led by General Atlantic, a leading global growth equity investor with a history of backing and scaling companies that transformed their industries, with participation from existing investors Notion Capital Project A and Seed Capital. Dixa will leverage the new funds to invest in product development, including potential new acquisitions (following Dixa’s acquisition of Melbourne-based Elevio in January 2021), and plans to quadr
V.E, Part of Moody’s ESG Solutions, Provides Second Party Opinion on the Kingdom of Spain’s Sovereign Green Bond Framework28.7.2021 15:30:00 EEST | Press release
Moody’s ESG Solutions Group announced today that V.E has provided a Second Party Opinion (SPO) on the Kingdom of Spain’s Sovereign Green Bond Framework. The Framework is aligned with the four core components of the Green Bond Principles 2021 and follows best market practices identified by V.E. Net proceeds of the bonds will exclusively be used to finance or refinance projects tied to the country’s environmental objectives, including renewable energy, biodiversity protection, and climate change adaptation. “The bonds issued under Spain’s Framework will provide an ‘advanced’ contribution to sustainability, the highest score on our four-point scale,” said Patrick Mispagel, MD – Sustainable Finance at Moody’s ESG Solutions. “Our assessment reflects that in many cases Spain’s Framework followed the detailed technical eligibility criteria of the EU Taxonomy Climate Delegated Act. We expect to see additional sovereign issuances as nations increasingly seek to raise capital to support climate
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)28.7.2021 15:15:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic neurological disorder that alters the sleep-wake cycle.3 EDS is a hallmark symptom of NT1 and is characterized by a person’s inability to stay awake and alert throughout the day, and falling asleep unintentionally or at inappropriate times on a daily basis.3,4 The FDA’s Breakthrough Therapy Designation process is designed to expedite the development and review of a drug that is intended to treat a serious condition, for which preliminary clinical evidence exists indicating it may demonstrate a substantial improvement over available therapies on at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom